FLGT News and Press, Fulgent Genetics Inc. From 05/03/22

Fulgent Genetics, Inc. (FLGT) Q1 2022 Earnings Conference Call May 3, 2022, 04:30 PM ET Company Participants Nicole Borsje - IR Ming Hsieh - CEO Brandon Perthuis - Chief Commercial Officer Larry Weiss - Chief Medical Officer Paul Kim - CFO Conference Call Participants Kevin DeGeeter - Oppenhe...

Fulgent Genetics (NASDAQ:FLGT) raised its 2022 revenue guidance to $660M (from $600M) but also lowered its full-year non-GAAP net income outlook to $6 per share (from $7). The genetic testing services company saw its net income in Q1 2022 decline 23% to ~154M ($4.93 per diluted share) compare...

The following slide deck was published by Fulgent Genetics, Inc. in conjunction with their 2022 Q1 earnings call. For further details see: Fulgent Genetics, Inc. 2022 Q1 - Results - Earnings Call Presentation

Fulgent Genetics press release (NASDAQ:FLGT): Q1 Non-GAAP EPS of $5.08 beats by $1.22. Revenue of $320.27M beats by $19.77M. Outlook: Q2: Total Revenue of approximately $125 million; Core Revenue of approximately $40 million, representing growth of 78% year-over-year. Consensus EPS ...

Revenue totals $320.3 million Core Revenue excluding COVID-19 NGS testing grows 59% year-over-year to $25.1 million Raises full year revenue outlook to $660 million from previously announced $600 million Raises full year core revenue outlook to $180 million from previously...

New oncology laboratory will focus on pathology and molecular services, particularly next generation sequencing Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics”, “Fulgent”, or the “Company”), a technology-based genetic testi...

Fulgent Genetics (NASDAQ:FLGT) Q1 consensus EPS estimate is $3.86 (-41.4% Y/Y) and consensus revenue estimate is $300.5M (-16.4% Y/Y). FLGT is scheduled to announce Q1 earnings results tomorrow, May 3, after market close. Over the last 2 years, FLGT has beaten EPS estimates 75%...

ABNB, ACHC, ADC, AHT, AIG, AIZ, AKAM, ALR, AMCR, AMD, ANDE, APPH, AQST, ATEN, AYX, BFAM, BGFV, BLKB, BNFT, BNL, BTG, BXC, CGBD, CHCT, CNDT, CNR, COKE, CRK, CRUS, CTSO, CWH, CZR, DENN, DHC, DMTK, EGY, EHTH, EIX, ENLC, ENVA, EQX, EXR, FLGT, FPI, FRSH, GLAD, GLRE, GNW, GPOR, GRBK, HASI, HLF, HRZ...

Investing in a growth stock can be risky if the catalyst behind its strong numbers disappears. Over the past couple of years, COVID-19 has led to some strong results for certain companies while others have faltered as a result of the pandemic. A stock that did well due to the pandemic w...

AVISTA CAPITAL PARTNERS COMPLETES SALE OF INFORM DIAGNOSTICS TO FULGENT GENETICS, INC. PR Newswire NEW YORK , April 27, 2022 /PRNewswire/ -- Avista Capital Partners ("Avista"), a leading private equity firm focused exclusively on healthcare, today announc...